Rein Therapeutics FY2025 operating loss narrows 22.2% to $(50.6) million; net loss narrows 20.7% to $(50) million

Rein Therapeutics reported a narrowed FY2025 operating loss of $50.6 million, down 22.2% from the previous year, with a net loss of $49.9 million compared to $62.9 million. Total operating expenses decreased to $50.6 million, including R&D expenses of $11.0 million and G&A expenses of $10.9 million. The impairment loss on intangible assets was $28.7 million. The company has $3.2 million in cash and expects to fund operations into Q2 2026 with additional proceeds from promissory notes.